Healthcare [ 11/13 ] | Medical Devices [ 114/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 9, 23 | -0.15 Increased by +70.66% | - |
| Aug 11, 23 | -0.12 Increased by +41.55% | - |
| May 12, 23 | -0.13 Increased by +40.91% | - |
| Mar 31, 23 | -0.11 Decreased by -10% | - |
| Nov 7, 22 | -0.51 Decreased by -326% | - |
| Aug 15, 22 | -0.2 Decreased by -122.22% | - |
| May 18, 22 | -0.22 Decreased by -3.57 K% | - |
| Mar 2, 22 | -0.1 Decreased by -687.4% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 24.49 K Decreased by -98.61% | -2.98 M Increased by +61.95% | Decreased by -12.15 K% Decreased by -2.63 K% |
| Jun 30, 23 | 28.55 K Decreased by -95.51% | -2.35 M Decreased by -19.65% | Decreased by -8.23 K% Decreased by -2.57 K% |
| Mar 31, 23 | 1.04 M Increased by +1.09 K% | -2.14 M Decreased by -0.88% | Decreased by -205.72% Increased by +91.53% |
| Dec 31, 22 | 1.04 M Increased by +3.83 K% | -2.13 M Decreased by -47.5% | Decreased by -205.29% Increased by +96.25% |
| Sep 30, 22 | 1.76 M Increased by +384.17% | -7.82 M Decreased by -574.18% | Decreased by -444.95% Decreased by -39.25% |
| Jun 30, 22 | 636.63 K Increased by +213.62% | -1.96 M Decreased by -161.91% | Decreased by -308.46% Increased by +16.49% |
| Mar 31, 22 | 87.2 K Increased by +4.01 K% | -2.12 M Decreased by -296.39% | Decreased by -2.43 K% Increased by +90.36% |
| Dec 31, 21 | 26.4 K Increased by +3.74 K% | -1.44 M Decreased by -222.14% | Decreased by -5.47 K% Increased by +91.62% |
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.